three years of appetite threads, summarised so you do not have to read them
Something I keep coming back to: three years of appetite threads, summarised so you do not have to read them.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Retitled to distinguish preclinical from clinical, which the original ran together.
Are we talking about receptor affinity or clinical potency?
GIP is the arm people argue about because the biology is genuinely unsettled
Which receptor arm are you attributing that to?
receptor distribution is why the side effects are where they are
receptor distribution is why the side effects are where they are
priya_guerrero is right that mechanism gives direction and not magnitude. Worth pinning.
Do you have the paper, or a summary of it?
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
[removed by moderator]
a mechanism you can state is not a mechanism you have demonstrated
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
incretin effect first, then everything else in this board makes sense
dose response is not linear and nobody should assume it is
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
This is the concept everything else on this board is downstream of.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
gastric emptying slows, it does not stop
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Does the effect persist with continued dosing or does tolerance develop?
Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.
read the discussion section, that is where the honesty lives
read the discussion section, that is where the honesty lives
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
- 1Glucose-dependent insulin secretion is why hypoglycaemia risk is low as…12 comments in this branch · started by u/rina_bergstrom
- 2Retitled to distinguish preclinical from clinical, which the original ran…7 comments in this branch · started by u/trialwatch_theo